Blocking of Histamine Release and IgE Binding to FcεRI on Human Basophils by Antibodies Produced in Camels.

Autor:	Khaled AQ; Department of Biological Sciences-Yarmouk University, Irbid, Jordan. khaled@monojo.com.jo.; Jordan Company for Antibody Production (MONOJO), Amman, Jordan., Sana Y; Department of Biological Sciences-Yarmouk University, Irbid, Jordan., Abdulrahman R; Department of Biological Sciences-Yarmouk University, Irbid, Jordan., Raida K; Department of Biotechnology and Genetic Engineering, Philadelphia University, Amman, Jordan., Sami AH; Department of Biological Sciences-Yarmouk University, Irbid, Jordan.; World Islamic Science and Education University (WISE), Amman, Jordan.
Jazyk:	angličtina
Zdroj:	Allergy, asthma & immunology research [Allergy Asthma Immunol Res] 2015 Nov; Vol. 7 (6), pp. 583-9. Date of Electronic Publication: 2015 Jun 25.
DOI:	10.4168/aair.2015.7.6.583
Abstrakt:	Purpose: The production of camel heavy-chain antihuman IgE (huIgE) that has the potential to block IgE-FcεRI interaction and histamine release by basophils. Methods: Camels were immunized with a synthetic loop peptide (SLP) designed in a multiple antigen peptide system (MAPS) forming SLP-MAPS immunogen. Camel polyclonal antibodies (PCAs) were produced, purified, characterized using Protein A & G, ELISA, and SDS-PAGE, and tested for their potency to block passive sensitization and histamine release of human basophils using flow cytometry (FCM) and ELISA, respectively. Results: FCM data indicated that camel conventional (IgG1) and heavy chain antibodies (HCAbs; IgG2, and IgG3) had blocking activities of 43.9%, 72%, and 96.6%, respectively. Moreover, both IgG2 and IgG3 achieved remarkable inhibition rates of 93.98% and 97.05% in histamine release, respectively, whereas the IgG1inhibiting activity was 60.05%. Conclusions: Camel PCAs produced against SLP-MAPS were capable of blocking the IgE-receptor interaction and the release of histamine by basophils with superiority to HCAbs. These findings may pave the way toward the possible use of camel anti-huIgE HCAbs as blocking antibodies in the treatment of IgE-mediated allergy and asthma.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu